Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory

Abstract

Purpose On January 1st, 2018, the ÖGZ (Austrian Society of Cytology) revised its cytological nomenclature to make it more similar to the 2015 Bethesda system. Following these changes, the Austrian Society of Gynecology and Obstetrics felt it necessary to revise the approach currently used in Austria to diagnose and treat CIN and to review the procedures to be followed when the quality of cytological specimens is unsatisfactory. It was not possible to adopt the German S3 guideline “Prevention of Cervical Cancer” in its entirety, because the Munich III gynecological cytology nomenclature used in Germany is not used in Austria. This made it necessary to compile a separate scientific opinion for Austria.

Methodology The OEGGG worked together with the ÖGZ (Austrian Society for Cytology), AGO Austria (Austrian Working Group for Gynecological Oncology), the AGK (Colposcopy Working Group), and physicians representing gynecologists in private practice. The different scientific associations nominated representatives, who attended the various meetings. After an in-depth analysis of the recent literature, three meetings and numerous votes by telephone, we were able to achieve a consensus about the contents of this guideline.

Recommendations The guideline provides recommendations for the diagnosis and treatment of CIN which take account of the gynecological cytology nomenclature used in Austria.

Key words

cervical intraepithelial neoplasia - cytology - colposcopy

Publikationsverlauf

Eingereicht: 27. September 2018

Angenommen: 15. Oktober 2018

Publikationsdatum:
14. Dezember 2018 (online)

• References/Literatur

• 1 Arbyn M, Snijders PJ, Meijer CJ. et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin Microbiol Infect 2015; 21: 817-826
• 2 Arbyn M, Redman CWE, Verdoodt F. et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol 2017; 18: 1665-1679
• 3 Arbyn M, Anttila A, Jordan J. et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. 2nd ed.. European Commission; 2008
• 4 Bornstein J, Bentley J, Bösze P. et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol 2012; 120: 166-172
• 5 Bosch FX, Lorincz A, Munoz N. et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265
• 6 Girardi F, Frey Tirri B, Küppers V. et al. Neue kolposkopische IFCPC-Nomenklatur der Cervix uteri (Rio de Janeiro 2011), Approbierte Darstellung und Erläuterung für Deutschland, Österreich und die deutschsprachige Schweiz. Frauenarzt 2012; 53: 1064-1066
• 7 Gosvig CF, Huusom LD, Andersen KK. et al. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization. Int J Cancer 2015; 137: 2927-2933
• 8 Holl K, Nowakowski AM, Powell N. et al. Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int J Cancer 2015; 137: 2858-2868
• 9 Joura EA, Garland SM, Paavonen J. et al. FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012; 344: 1401
• 10 Joura EA, Giuliano AR, Iversen OE. et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. NEJM 2015; 372: 711-723
• 11 Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)?. Gynecol Oncol 2013; 130: 264-268
• 12 Kjaer SK, Frederiksen K, Munk C. et al. Long-term absolute risk of cervical intraepithelial neoplasia Grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-1488
• 13 Kurman RJ, Carcangiu ML, Herrington S. et al. WHO Classification of Tumours of Female Reproductive Organs. Lyon: IARC Press; 2014
• 14 Kyrgiou M, Athanasiou A, Paraskevaidi M. et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016; 354: 3633
• 15 Meijer CJ, Berkhof J, Castle PE. et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520
• 16 Moss EL, Arbyn M, Dollery E. et al. European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013; 170: 255-258
• 17 Massad LS, Einstein MH, Huh WK. et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol 2013; 121: 829-846
• 18 Nayar R, Wilbur BC. The Bethesda System: The Bethesda System for Reporting Cervical Cytology. 3rd ed.. Springer; 2015
• 19 Braune G, Fiedler T, Hefler L. et al. OEGGG Positionspapier HPV. Online (last access: 27.09.2018): https://www.oeggg.at/leitlinien-stellungnahmen/gynäkologie-1/
• 20 Quaas J, Reich O, Frey Tirri B. et al. Explanation and use of the Colposcopy Terminology of the IFCPC (International Federation for Cervical Pathology and Colposcopy) Rio 2011. Geburtsh Frauenheilk 2013; 73: 904-907
• 21 Regitnig P. Die neue Nomenklatur der ÖGZ und ÖGPath/IAP Austria mit Erläuterungen. Spectrum Pathologie 2017; 1: 7-9
• 22 Reich O, Lahousen M, Pickel H. et al. Cervical intraepithelial neoplasia III: long-term follow-up after cold-knife conization with involved margins. Obstet Gynecol 2002; 99: 193-196
• 23 Reich O, Regauer S, Marth C. et al. Precancerous Lesions of the Cervix, Vulva and Vagina According to the 2014 WHO Classification of Tumors of the Female Genital Tract. Geburtsh Frauenheilk 2015; 75: 1018-1020
• 24 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Prävention des Zervixkarzinoms; Langversion 1.0 – Dezember 2017; AWMF-Registernummer 015/027OL. Online (last access: 27.09.2018): http://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom-praevention/
• 25 Stoler MH, Castle PE, Solomon D. American Society for Colposcopy and Cervical Pathology. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol 2007; 127: 335-357
• 26 Tainio K, Athanasiou A, Tikkinen KAO. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ 2018; 360: 499
• 27 Walboomers JM, Jacobs MV, Manos MM. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19
• 28 Wentzensen N, Walker JL, Gold MA. et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. J Clin Oncol 2015; 33: 83-89